EUVIMED · CrossrefZeitschrift
Lupus Science & Medicine
ISSN 2053-8790 · BMJ
Neueste Artikel
Risk-stratified effectiveness of direct oral anticoagulants versus vitamin K antagonists in thrombotic antiphospholipid syndrome: a prospective cohort study
Measurement of kidney disease in a novel multidomain treatment response measure for SLE clinical trials
Lupus Nexus: developing a prospective registry, biorepository and data exchange platform to foster global collaborations, accelerate research innovation and advance precision medicine in lupus
Free mycophenolic acid exposure for therapeutic drug monitoring in paediatric lupus nephritis: associations with treatment response and haematologic toxicity
Grading of intrarenal tertiary lymphoid structure-like aggregates and association with early treatment response in proliferative lupus nephritis
Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study
Effect of upadacitinib and ABBV-599 on biomarkers in SLE: results from the phase 2 SLEek study
Impact of deucravacitinib on arthritis in patients with systemic lupus erythematosus: results from the phase II PAISLEY SLE study
Loss-of-function variant of the immunoregulator TMEM176B is associated with progression to ESKD in SLE
Real-world discontinuation of immunosuppressive therapy after proliferative lupus nephritis: the overlooked impact of non-adherence (MASSILUP-WIN)
Pulmonary function, functional capacity and physical activity in patients with SLE: a cross-sectional study
Maternal and neonatal outcomes in SLE: comparison of 430 pregnancies from the French GR2 study with 1720 pregnancies from French perinatal surveys
Longitudinal clinical course and long-term outcomes of SLE-associated interstitial lung disease
Pulmonary diseases in SLE: a population-based cross-sectional study
Evaluation of clinical, histological and biomarker response after initial therapy of lupus nephritis
Measurements of urinary biomarkers at 2 years following a lupus nephritis flare are associated with subsequent renal outcomes
Statin therapy in systemic lupus erythematosus: a meta-analysis of disease activity and inflammatory biomarkers
Intrathecal injection of rituximab inhibits microglial M1 polarisation to alleviate neuropsychiatric SLE symptoms via the cAMP/PKA/CREB signalling pathway
Alterations in the DTI-ALPS index and choroid plexus volume as brain–immune interfacing indicators in neuropsychiatric lupus erythematosus with inflammatory phenotype
Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry
Measurement of haemolytic anaemia in a novel treatment response measure for SLE clinical trials
Biomarker-stratified efficacy and safety of biologics in systemic lupus erythematosus: a systematic review and meta-analysis
Cells’ survival pattern of kidney macrophages and epithelial cells in lupus nephritis is influenced by glycolysis
Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluation
Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus
Beyond renal response: sustained systemic disease control protects against adverse long-term outcomes in lupus nephritis
Anti-ribosomal-P protein antibodies and systemic lupus erythematosus (SLE): in a cross-sectional study of Danish adult patients with SLE, no significant association is found between anti-ribosomal-P and neuropsychiatric SLE
Informing trial measurement in systemic lupus erythematosus: frequency of domain-specific disease activity in a multinational cohort
TSPO PET/MR in neuropsychiatric lupus: neuroinflammatory metabolic signatures and diagnostic biomarkers
Inflammation in areas of fibrosis precedes loss of kidney function in lupus nephritis
EUVIMED